Phase II study on lapatinib in advanced EGFR-positive chordoma (Q33274760)

25 July 2017

title

Phase II study on lapatinib in advanced EGFR-positive chordoma (English)

1 reference

25 July 2017

0 references

1

0 references

Alessandro Gronchi

15

0 references

Elena Palassini

E Palassini

11

0 references

Tiziana Negri

T Negri

10

0 references

Fabio Bozzi

F Bozzi

4

0 references

Carlo Morosi

C Morosi

6

0 references

Emanuela Palmerini

E Palmerini

13

0 references

Elena Tamborini

E Tamborini

2

0 references

Luigi Mariani

L Mariani

14

0 references

author name string

S Lo Vullo

3

1 reference

25 July 2017

A Messina

5

1 reference

25 July 2017

A Casale

7

1 reference

25 July 2017

F Crippa

8

1 reference

25 July 2017

E Conca

9

1 reference

25 July 2017

A Marrari

12

1 reference

25 July 2017

S Pilotti

16

1 reference

25 July 2017

P G Casali

17

1 reference

25 July 2017

publication date

4 April 2013

1 reference

25 July 2017

1 reference

25 July 2017

volume

24

1 reference

25 July 2017

issue

7

1 reference

25 July 2017

page(s)

1931-1936

1 reference

Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Chordomas of the skull base: surgical management and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Chordoma: incidence and survival patterns in the United States, 1973-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Metastatic disease from spinal chordoma: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Chemotherapeutic treatment of malignant chordoma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Phase II study of imatinib in advanced chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Response to imatinib plus sirolimus in advanced chordoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Response to erlotinib in a patient with treatment refractory chordoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

AXL and acquired resistance to EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT117

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT117

1 reference

25 July 2017

1 reference